Report : North America Kidney Disease Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product (Diagnosis and Treatment); End User (Hospitals, Diagnostic Laboratories, and Others); and Country
According to The Insight Partners market research study of ‘North America Kidney Disease Market Forecast to 2027 - COVID-19 Impact and Analysis by product, and end-user’ the North America kidney disease market is expected to reach US$ 42,462.1 million in 2027 from US$ 25,483.5 in 2019. The market is estimated to grow with a CAGR of 6.7% from 2020-2027. The report provides trends prevailing in the North America kidney disease market and the factors driving market along with those that act as hindrances.
Based on the product, the North America the kidney disease market, is segmented into diagnosis and treatment. The diagnosis segment held the largest share of the market in 2019, also the same segment is anticipated to register the highest CAGR in the market during the forecast period. The Chronic kidney disease (CKD) can be diagnosed with blood and urine tests. Diagnosis of kidney disease is made with various tests such as blood tests, urine tests, imaging tests, and others. The tests must be performed in conditions such as diabetes, high blood pressure, heart disease, and a family history of kidney failure. Early kidney disease usually doesn’t have any symptoms. Testing is the only way to know how well kidneys are working.
The growth of the market is attributed to some key driving factors such as an increasing prevalence of chronic kidney related diseases and a high growth in aging population. However, the market is expected experiencing slow growth during the forecast period owing to failure in diagnosing cases of kidney diseases.
Abbott, Siemens AG, and F. Hoffmann-La Roche Ltd are among the leading companies operating in the North America kidney disease market.
The report segments North America Kidney Disease Market as Follows: